National Comprehensive Cancer Network

Crystal S. Denlinger, MD, FACP, has been named the new CEO of National Comprehensive Cancer Network.

Cancer centers in the United States continue to experience critical shortages of commonly used platinum-based chemotherapies, according to survey results from National Comprehensive Cancer Network.

SAN ANTONIO — Use of low-dose tamoxifen conferred a sustained reduction in risk for recurrence among women with noninvasive breast cancer, according to updated results from the randomized, phase 3 TAM-01 trial.

National Comprehensive Cancer Network has updated its recommendations on COVID-19 vaccination for patients with cancer.

Cancer centers, advocacy groups and other organizations have ramped up efforts to reduce disparities across the cancer care continuum, according to presenters at the virtual National Comprehensive Cancer Network 2022 Annual Conference.

Indiana University Melvin and Bren Simon Comprehensive Cancer network has become the newest National Comprehensive Cancer Network member institution.

National Comprehensive Cancer Network has issued updated guidance on COVID-19 vaccination and pre-exposure prophylaxis for patients with cancer.

Indications for which cancer drugs receive accelerated approval often remain on drug labeling after confirmatory trials show no improvement in the primary efficacy endpoint, results of a retrospective, observational study showed.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.

Mary B. Daly, MD, PhD, FACP, received National Comprehensive Cancer Network’s Rodger Winn Award.